Who Owns Dyne Therapeutics Stock?
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 104.76%
- Institutions (% of float)
- 105.29%
- Held by insiders
- 0.50%
- Institutional holders
- 360
- Institutions 99.5%
- Insiders 0.5%
- Public and other 0.0%
Who owns Dyne Therapeutics stock?
Institutional investors own about 104.8% of Dyne Therapeutics's shares, spread across 360 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.50% of DYN.
The largest institutional holders are T. Rowe Price Investment Management, Inc. (16.50%), Blackrock Inc. (7.73%) and Jupiter Topco LLC (6.40%). Together, the top 10 institutions control 56.0% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their DYN positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of DYN
| Institution | Shares | % Held | Change |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30.91M | 16.50% | +0.4% |
| Blackrock Inc. | 14.47M | 7.73% | +16.7% |
| Jupiter Topco LLC | 12.00M | 6.40% | +100.0% |
| FMR, LLC | 11.15M | 5.95% | -0.5% |
| State Street Corporation | 8.16M | 4.36% | +9.4% |
| Vanguard Capital Management LLC | 7.55M | 4.03% | +19.7% |
| Orbis Allan Gray Ltd | 7.01M | 3.74% | +3.6% |
| Vanguard Portfolio Management LLC | 4.69M | 2.50% | +15.9% |
| TCG Crossover Management, LLC | 4.62M | 2.46% | 0.0% |
| Geode Capital Management, LLC | 4.40M | 2.35% | +17.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of DYN
| Fund | Shares | % Held |
|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 7.00M | 3.74% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 4.60M | 2.46% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.47M | 2.39% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4.35M | 2.32% |
| iShares Trust-iShares Russell 2000 ETF | 3.99M | 2.13% |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.81M | 2.03% |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 3.28M | 1.75% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 3.25M | 1.73% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.16M | 1.69% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 2.98M | 1.59% |
Frequently asked questions
Who is the largest shareholder of Dyne Therapeutics?
T. Rowe Price Investment Management, Inc. is the largest institutional shareholder of DYN, owning 16.50% of shares outstanding (30.91M shares) as of its latest 13F filing.
What percentage of Dyne Therapeutics is owned by institutions?
Institutions own about 104.8% of DYN shares and 105.3% of the public float.
How much of Dyne Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.50% of DYN shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.